Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation: the present and future.

H Van Aken1, C Bode, H Darius

  • 1Klinik und Poliklinik für Anästhesiologie. Westf. Wilhelms-Universität, Münster, Germany.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|July 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2014
Same author

[A modular retraction system (VarioLift) for laparoscopy without pneumoperitoneum].

Zentralblatt fur Chirurgie·2012
Same author

[Thrombosis prophylaxis in surgery. What is the evidence?].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2011
Same author

[Preventing venous thromboembolism].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2007
Same author

[Graduated compression stockings in surgery -- optional or obligatory? Commentary invited by the editorship].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2004
Same author

[CO2 pneumoperitoneum inhibits in vitro proliferation of human carcinoma cells].

Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
Same journal

Association of Protein C, but Not Protein S or Antithrombin With Ischemic Stroke: Bidirectional Two-Sample Mendelian Randomization and Meta-Analysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Risk Prediction Models for Deep Vein Thrombosis in Patients With Spontaneous Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Efficacy of an Integrated Nursing Protocol for the Management of Postoperative Upper Limb Circulatory Complications Following Transradial Coronary Intervention.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Dual-Channel Inhibition With Rivaroxaban and Aspirin for Thromboprophylaxis in Patients With Long-Term Inferior Vena Cava Filter Implantation: A Two-Center Cohort Study.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Association Between TNF-Alpha Levels and Atrial Fibrillation Outcomes: A Systematic Review and Meta-Analysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Interpretation of Prothrombin Time and Activated Partial Thromboplastin Time Mixing Studies Using Predefined Algorithms.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
See all related articles

Direct thrombin inhibitors offer improved anticoagulation for preventing and treating blood clots. Newer oral direct thrombin inhibitors represent a significant advancement in managing thromboembolic disorders safely and effectively.

Area of Science:

  • Biochemistry and Pharmacology
  • Cardiovascular Medicine
  • Drug Discovery

Background:

  • Thrombin is a key regulator of blood coagulation, making it a primary target for treating thromboembolic disorders like deep vein thrombosis and pulmonary embolism.
  • Current anticoagulants, heparins and coumarins, have limitations including unpredictable effects, bleeding risks, and the need for monitoring.
  • Low-molecular-weight heparins offer predictability but require subcutaneous administration and cannot inhibit clot-bound thrombin, risking rebound thrombosis.

Purpose of the Study:

  • To review the evolution and therapeutic potential of direct thrombin inhibitors (DTIs) in anticoagulation.
  • To highlight the advantages of DTIs over traditional anticoagulants in managing thromboembolic conditions.
  • To discuss the development of safer and more effective DTI therapies, including oral formulations.

Related Experiment Videos

Main Methods:

  • Review of existing literature on thrombin inhibitors and anticoagulation therapies.
  • Analysis of the mechanisms of action, pharmacokinetics, and clinical outcomes of various anticoagulant agents.
  • Comparison of direct thrombin inhibitors (covalent and noncovalent) with indirect inhibitors.

Main Results:

  • Direct thrombin inhibitors effectively target both free and clot-bound thrombin, addressing limitations of heparins.
  • Reversible noncovalent DTIs demonstrate improved safety, specificity, and predictability compared to covalent DTIs.
  • Oral DTIs, such as ximelagatran, show promise for breakthrough advancements in thrombosis prophylaxis and treatment.

Conclusions:

  • Direct thrombin inhibitors represent a significant therapeutic advance in anticoagulation.
  • The development of reversible, noncovalent, and oral DTIs offers safer, more predictable, and convenient options for managing thromboembolic disorders.
  • Further research and clinical application of oral DTIs are expected to revolutionize thrombosis treatment.